Lower Plasma Adiponectin Levels Are Associated with Larger Tumor Size and Metastasis in Clear-Cell Carcinoma of the Kidney
Lower Plasma Adiponectin Levels Are Associated with Larger Tumor Size and Metastasis in Clear-Cell Carcinoma of the Kidney
复制标题
DOI：
10.1016/j.eururo.2008.02.044
复制
发表时间：
2008-10-01
期刊：
影响因子：
23.4
通讯作者：
Kapoor, Anil
中科院分区：
文献类型：
--
作者：
Pinthus, Jehonathan H.;Kleinmann, Nir;Kapoor, Anil
目的：探讨血浆脂联素水平与肾细胞癌 (RCC) 之间可能存在的关系。脂联素是脂肪细胞分泌的细胞因子，是一种有效的抗血管生成因子。测量肾细胞癌患者血浆脂联素水平以及肿瘤脂联素受体 R1 和 R2 (AdipoR1&2) 表达水平，并将其与疾病特征相关联。方法：采用特异性 ELISA 测定，对 42 名患者的术前血浆样本进行三次重复分析，检测脂联素水平。所有患者均患有透明细胞肾细胞癌，其中 15 名患者患有转移性疾病。糖尿病患者被排除在外；所有患者的肾功能均正常。对15例患者肾细胞癌及周围正常肾组织的AdipoR1&2表达进行比较分析（免疫印迹法）。结果：血浆脂联素水平的平均值、中位数和范围分别为6.33、5.84和1-25.2μg/ml。血浆脂联素水平与肿瘤大小之间存在很强的负相关性，>= 4 cm 的肿瘤中脂联素水平显着较低（p < 0.01）。转移性和非转移性患者的中位脂联素水平分别为 4.08 和 7.4 μg/ml (p = 0.029)。注意到高 Fuhrman 等级（3 级和 4 级 vs 1 级和 2 级）脂联素水平显着降低的趋势 (p = 0.057)。 40%的病例中，与患者周围正常肾组织相比，AdipoR1&R2在肿瘤组织中的表达较低。转移性肿瘤表达较低水平的 AdipoR2。体重指数与脂联素水平不呈负相关。结论：较低的血液脂联素水平与透明细胞肾细胞癌的侵袭性呈正相关，并且有可能用作生物标志物。 (C) 2008 年欧洲泌尿外科协会。由 Elsevier B.V. 出版。保留所有权利。
Objectives: To examine a possible relationship between plasma adiponectin levels and renal cell carcinoma (RCC). Adiponectin, a cytokine secreted by adipocytes, is a potent antiangiogenic factor. Plasma levels of adiponectin in patients with RCC and tumor adiponectin receptors R1 and R2 (AdipoR1&2) expression levels were measured and correlated with disease characteristics.Methods: Preoperative plasma samples from 42 patients were analyzed in triplicate for adiponectin levels with a specific ELISA assay. All patients had clear-cell RCC, including 15 with metastatic disease. Diabetic patients were excluded; all had normal renal function. The RCC and surrounding normal renal tissue were comparatively analyzed for AdipoR1&2 expressions (immunoblotting) in 15 patients.Results: Mean, median, and range of plasma adiponectin levels were 6.33, 5.84, and 1-25.2 mu g/ml, respectively. A strong inverse correlation was found between plasma adiponectin levels and tumor size with significantly lower levels of adiponectin in tumors >= 4 cm (p < 0.01). The median adiponectin levels in metastatic and non-metastatic patients were 4.08 and 7.4 mu g/ml, respectively (p = 0.029). A trend toward significant lower adiponectin levels in high versus low Fuhrman grade (3 and 4 vs. 1 and 2) was noted (p = 0.057). Expression of AdipoR1&R2 was found to be lower in tumor tissue compared with the patient's normal surrounding kidney tissues in 40% of the cases. Metastatic tumors expressed lower levels of AdipoR2. Body mass index was not inversely correlated with adiponectin levels.Conclusions: Lower blood levels of adiponectin are positively associated with clear-cell RCC aggressiveness and could potentially be used as a biomarker. (C) 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved.